Skip to content

Study · In vitro (cells) · 2013

4 results

Specificity of antimicrobial peptide LL-37 to neutralize periodontopathogenic lipopolysaccharide activity in human oral fibroblasts.

Suphasiriroj W, Mikami M, Shimomura H, Sato S

Journal of periodontology23 Mar 2012Cited by 18 (Europe PMC)

PMID22443521 (opens in a new tab)DOI10.1902/jop.2012.110652 (opens in a new tab)PepBankPUB-22443521
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human periodontal ligament fibroblasts, LL‑37 reduced IL-8 production induced by periodontopathogenic LPS.

    In plain wordsIn cells, LL‑37 lowered the inflammatory signal IL-8 triggered by gum-disease bacteria LPS, compared with LPS alone.

    Peptide
    LL-37
    Outcome
    DecreaseIL-8 production after periodontopathogenic LPS in PDLF
    Study

    humann: not reported in source

    Human periodontal ligament fibroblasts (PDLF)
    Comparator
    LPS-treated cells without LL-37
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 µg/mL · 18 hoursAs given in this study (human).

    Source sentences

    Summary
    After neutralization with LL-37, both PDLF and GF showed a statistically significant reduction in IL-8 production compared with LPS-treated groups without LL-37 (P <0.01)
    1 context sentence
    Summary · context
    Human periodontal ligament fibroblasts (PDLF) and gingival fibroblasts (GF) were cultured from biopsies of periodontal ligament and gingival tissues. After cell confluence in 24-well plates, LPS (10 μg/mL) from Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Aggregatiba…
  2. 02LabIn vitro (cells)Mechanism

    In human gingival fibroblasts, LL‑37 reduced IL-8 production induced by periodontopathogenic LPS.

    In plain wordsIn cells, LL‑37 lowered the inflammatory signal IL-8 triggered by gum-disease bacteria LPS, compared with LPS alone.

    Peptide
    LL-37
    Outcome
    DecreaseIL-8 production after periodontopathogenic LPS in GF
    Study

    humann: not reported in source

    Human gingival fibroblasts (GF)
    Comparator
    LPS-treated cells without LL-37
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 µg/mL · 18 hoursAs given in this study (human).

    Source sentences

    Summary
    After neutralization with LL-37, both PDLF and GF showed a statistically significant reduction in IL-8 production compared with LPS-treated groups without LL-37 (P <0.01)
    1 context sentence
    Summary · context
    Human periodontal ligament fibroblasts (PDLF) and gingival fibroblasts (GF) were cultured from biopsies of periodontal ligament and gingival tissues. After cell confluence in 24-well plates, LPS (10 μg/mL) from Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Aggregatiba…
  3. 03LabIn vitro (cells)Mechanism

    The percentage reduction in IL-8 production with LL‑37 appeared higher in periodontal ligament fibroblasts than in gingival fibroblasts.

    In plain wordsIn cells, LL‑37 seemed to lower IL-8 more in periodontal ligament cells than in gum cells.

    Peptide
    LL-37
    Outcome
    Not applicableIL-8 reduction in PDLF compared with GF
    Study

    humann: not reported in source

    PDLF and GF
    Comparator
    Gingival fibroblasts (GF)
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 µg/mL · 18 hoursAs given in this study (human).

    Source sentences

    Summary
    the percentage of reduction in IL-8 production in PDLF appeared to be higher than in GF.
    1 context sentence
    Summary · context
    Human periodontal ligament fibroblasts (PDLF) and gingival fibroblasts (GF) were cultured from biopsies of periodontal ligament and gingival tissues. After cell confluence in 24-well plates, LPS (10 μg/mL) from Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Aggregatiba…
  4. 04LabIn vitro (cells)Mechanism

    The percentage reduction in IL-8 production by LL‑37 varied considerably between LPS from different periodontopathogens.

    In plain wordsIn cells, how much LL‑37 lowered IL-8 depended on which gum-disease bacterium the LPS came from.

    Peptide
    LL-37
    Outcome
    MixedIL-8 reduction by LL-37 across LPS types
    Study

    humann: not reported in source

    PDLF and GF
    Comparator
    LPS from other periodontopathogenic species
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 µg/mL · 18 hoursAs given in this study (human).

    Source sentences

    Summary
    In addition, the percentage of reduction in IL-8 production varied considerably according to each periodontopathogenic LPS.
    1 context sentence
    Summary · context
    Human periodontal ligament fibroblasts (PDLF) and gingival fibroblasts (GF) were cultured from biopsies of periodontal ligament and gingival tissues. After cell confluence in 24-well plates, LPS (10 μg/mL) from Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Aggregatiba…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:58 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.